# Oxygen Atomizing Inhalation of EGCG in the Treatment Interstitial Pneumonia in Cancer Patients

> **NCT05758571** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shandong Cancer Hospital and Institute** · enrollment: 78 (estimated)

## Conditions studied

- Interstitial Pneumonia
- Neoplasms Malignant

## Interventions

- **DRUG:** EGCG

## Key facts

- **NCT ID:** NCT05758571
- **Lead sponsor:** Shandong Cancer Hospital and Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-05
- **Primary completion:** 2023-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2023-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05758571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05758571, "Oxygen Atomizing Inhalation of EGCG in the Treatment Interstitial Pneumonia in Cancer Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05758571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*